Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.
Barreto J, Martins M, Pascoa M, Medorima STK, Bonilha I, Jesus DC, Carbonara CEM, Quadros KRS, Assato B, Campos-Staffico AM, Júnior GG, Nadruz W, de Oliveira RB, Sposito AC.
Barreto J, et al. Among authors: quadros krs.
Res Sq [Preprint]. 2023 Oct 19:rs.3.rs-3434207. doi: 10.21203/rs.3.rs-3434207/v1.
Res Sq. 2023.
PMID: 37886458
Free PMC article.
Updated.
Preprint.